Linked Life Data

20889347

Source:http://linkedlifedata.com/resource/pubmed/id/20889347

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20889347rdf:typepubmed:Citationlld:pubmed
pubmed-article:20889347lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0031268lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0169582lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0887820lld:lifeskim
pubmed-article:20889347lifeskim:mentionsumls-concept:C0599278lld:lifeskim
pubmed-article:20889347pubmed:issue21lld:pubmed
pubmed-article:20889347pubmed:dateCreated2010-10-18lld:pubmed
pubmed-article:20889347pubmed:abstractTextLocated in presynaptic cholinergic nerve terminals, the vesicular acetylcholine transporter (VAChT) represents a potential target for quantitative visualization of early degeneration of cholinergic neurons in Alzheimer's disease using PET. Benzovesamicol derivatives are proposed as radioligands for this purpose. We report QSAR studies of vesamicol and benzovesamicol derivatives taking into account the stereoselectivity of the VAChT binding site. Use of different data sets and different models in this study revealed that both enantiomers of 5-fluoro-3-(4-phenyl-piperidin-1-yl)-1,2,3,4-tetrahydro-naphthalen-2-ol (5-FBVM) are promising candidates, with predicted VAChT affinities between 6.1 and 0.05 nM. The synthesis of enantiopure (R,R)- and (S,S)-5-FBVM and their corresponding triazene precursors for future radiofluorination is reported. Both enantiomers exhibited high in vitro affinity for VAChT [(+)-5-FBVM: K(i)=6.95 nM and (-)-5-FBVM: K(i)=3.68 nM] and were selective for ?(2) receptors (?70-fold), only (+)-5-FBVM is selective for ?(1) receptors (?fivefold). These initial results suggest that (+)-(S,S)-5-FBVM warrants further investigation as a potential radioligand for in vivo PET imaging of cholinergic nerve terminals.lld:pubmed
pubmed-article:20889347pubmed:languageenglld:pubmed
pubmed-article:20889347pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:citationSubsetIMlld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20889347pubmed:statusMEDLINElld:pubmed
pubmed-article:20889347pubmed:monthNovlld:pubmed
pubmed-article:20889347pubmed:issn1464-3391lld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:EmondPatrickPlld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:MavelSylvieSlld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:GuilloteauDen...lld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:BrustPeterPlld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:Deuther-Conra...lld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:WenzelBarbara...lld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:AnderluhMarko...lld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:GlöcknerJanaJlld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:KovacMitjaMlld:pubmed
pubmed-article:20889347pubmed:authorpubmed-author:MéheuxNathali...lld:pubmed
pubmed-article:20889347pubmed:copyrightInfoCopyright © 2010 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:20889347pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20889347pubmed:day1lld:pubmed
pubmed-article:20889347pubmed:volume18lld:pubmed
pubmed-article:20889347pubmed:ownerNLMlld:pubmed
pubmed-article:20889347pubmed:authorsCompleteYlld:pubmed
pubmed-article:20889347pubmed:pagination7659-67lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:meshHeadingpubmed-meshheading:20889347...lld:pubmed
pubmed-article:20889347pubmed:year2010lld:pubmed
pubmed-article:20889347pubmed:articleTitle3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT).lld:pubmed
pubmed-article:20889347pubmed:affiliationUniversité François-Rabelais de Tours, INSERM U930, CHRU, Hôpital Bretonneau, Service de Médecine Nucléaire, 37000 Tours, France.lld:pubmed
pubmed-article:20889347pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20889347pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:20889347lld:chembl